A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

OncoImmunology

Volumn 6, Issue 10, 2017, Pages

  David, Justin M ^a   Dominguez, Charli ^a   McCampbell, Kristen K ^a   Gulley, James L ^a   Schlom, Jeffrey ^a   Palena, Claudia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EMT; fusion protein; immunotherapy; NSCLC; PD L1; TGF 1

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AVELUMAB; GILVETMAB; M 7824; SMAD2 PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE ESCALATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER CELL LINE; MESENCHYME CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 85027339130     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1349589     Document Type: Article

References (59)

1. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30(17):2046-2054; PMID:22547592; https://doi.org/10.1200/JCO.2011.38.4032
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-2454; PMID:22658127; https://doi.org/10.1056/NEJMoa1200690
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26):2455-2465; PMID:22658128; https://doi.org/10.1056/NEJMoa1200694
4. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192(7):1027-1034; PMID:11015443; https://doi.org/10.1084/jem.192.7.1027
5. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2(3):261-268; PMID:11224527; https://doi.org/10.1038/85330
6. Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, Korthauer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003; 170(7):3637-3644; PMID:12646628; https://doi.org/10.4049/jimmunol.170.7.3637
7. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8(8):793-800; PMID:12091876
8. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10(15):5094-5100; PMID:15297412; https://doi.org/10.1158/1078-0432.CCR-04-0428
9. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14(8):535-546; PMID:25056707; https://doi.org/10.1038/nrc3775
10. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66(4):271-289; PMID:27253694; https://doi.org/10.3322/caac.21349
11. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17):1627-1639; PMID:26412456; https://doi.org/10.1056/NEJMoa1507643
12. Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33(18_suppl):LBA109; PMID:28147722; https://doi.org/10.1200/jco.2015.33.18_suppl.lba109
13. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-dependent cellular cytotoxicity activity of a novel Anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015; 3(10):1148-1157; PMID:26014098; https://doi.org/10.1158/2326-6066.CIR-15-0059
14. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ, Leach J, Edenfield WJ, Wang D, Grote HJ, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 2017; 18(5):599-610; PMID:28373005; https://doi.org/10.1016/S1470-2045(17)30240-1
15. Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017; 18(5):587-598; PMID:28373007; https://doi.org/10.1016/S1470-2045(17)30239-5
16. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-5074; PMID:24714771; https://doi.org/10.1158/1078-0432.CCR-13-3271
17. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515(7528):568-571; PMID:25428505; https://doi.org/10.1038/nature13954
18. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528):563-567; PMID:25428504; https://doi.org/10.1038/nature14011
19. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6):1420-1428; PMID:19487818; https://doi.org/10.1172/JCI39104
20. David JM, Dominguez C, Palena C. Pharmacological and immunological targeting of tumor mesenchymalization. Pharmacol Ther 2017; 170:212-225; PMID:27916651; https://doi.org/10.1016/j.pharmthera.2016.11.011
21. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009; 15(3):195-206; PMID:19249678; https://doi.org/10.1016/j.ccr.2009.01.023
22. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013; 73(8):2418-2427; PMID:23436798; https://doi.org/10.1158/0008-5472.CAN-12-2432
23. Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Res 2014; 74(9):2510-2519; PMID:24626094; https://doi.org/10.1158/0008-5472.CAN-13-1894
24. Akalay I, Tan TZ, Kumar P, Janji B, Mami-Chouaib F, Charpy C, Vielh P, Larsen AK, Thiery JP, Sabbah M, et al. Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene 2015; 34(17):2261-2271; PMID:24931170; https://doi.org/10.1038/onc.2014.151
25. David JM, Hamilton DH, and Palena C. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology 2016; 5(4):e1117738; PMID:27141403; https://doi.org/10.1080/2162402X.2015.1117738
26. Goswami MT, Reka AK, Kurapati H, Kaza V, Chen J, Standiford TJ, Keshamouni VG. Regulation of complement-dependent cytotoxicity by TGF-beta-induced epithelial-mesenchymal transition. Oncogene 2016; 35(15):1888-1898; PMID:26148233; https://doi.org/10.1038/onc.2015.258
27. Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y. CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis 2013; 30(4):393-405; PMID:23143679; https://doi.org/10.1007/s10585-012-9545-6
28. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5:5241; PMID:25348003; https://doi.org/10.1038/ncomms6241
29. Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene 2017; 36(28):4037-4046, Mar 13 [Epub ahead of print]; PMID:28288138; https://doi.org/10.1038/onc.2017.47
30. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015; 14:149; PMID:26245467; https://doi.org/10.1186/s12943-015-0421-2
31. Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y. Drug resistance originating from a TGF-beta/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol 2016; 48(5):1825-1836; PMID:26984042; https://doi.org/10.3892/ijo.2016.3419
32. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 2016; 22(14):3630-3642; PMID:26851185; https://doi.org/10.1158/1078-0432.CCR-15-1434
33. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013; 13(11):788-799; PMID:24132110; https://doi.org/10.1038/nrc3603
34. Strauss J, Heery CR, Schlom J, Madan RA, Lamping E, Marte J, Cordes L, Lan Y, Mahnke L, Helwig C, et al. A phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors (abstr). TGF-ß Immunity Inflammation Cancer Keystone Symposia. Mol Cell Biol 2017
35. Gulley JL, Heery CR, Schlom J, Madan RA, Cao L, Lamping E, Marte JL, Cordes LM, Christensen O, Helwig C, et al. Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. J Clin Oncol 2017; 35:15_suppl, 3006-3006. https://doi.org/10.1200/JCO.2017.35.15_suppl.3006
36. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4(8):657-665; PMID:12923528; https://doi.org/10.1038/nrm1175
37. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 2016; 108(1); pii:djv303; PMID:26577528; https://doi.org/10.1093/jnci/djv303
38. Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 2016; 7(29):45370-45384; PMID:27248318; https://doi.org/10.18632/oncotarget.9659
39. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007; 101(1):9-33; PMID:17340614; https://doi.org/10.1002/jcb.21255
40. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580(3):755-762; PMID:16413538; https://doi.org/10.1016/j.febslet.2005.12.093
41. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 2016; 22(3):609-620; PMID:26420858; https://doi.org/10.1158/1078-0432.CCR-15-0876
42. Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 2016; 7(13):15901-15914; PMID:26893364; https://doi.org/10.18632/oncotarget.7431
43. Kim S, Koh J, Kim MY, Kwon D, Go H, Kim YA, Jeon YK, Chung DH. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol 2016; 58:7-14; PMID:27473266; https://doi.org/10.1016/j.humpath.2016.07.007
44. Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, Takemoto T, Mitsudomi T. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 2016; 98:69-75; PMID:27393509; https://doi.org/10.1016/j.lungcan.2016.04.021
45. Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep 2012; 28(2):615-621; PMID:22614805; https://doi.org/10.3892/or.2012.1822
46. Song S, Yuan P, Wu H, Chen J, Fu J, Li P, Lu J, Wei W. Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol 2014; 20(1):117-123; PMID:24606770; https://doi.org/10.1016/j.intimp.2014.02.027
47. Baas M, Besancon A, Goncalves T, Valette F, Yagita H, Sawitzki B, Volk HD, Waeckel-Enee E, Rocha B, Chatenoud L, et al. TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 2016; 5:e08133; PMID:26824266; https://doi.org/10.7554/eLife.08133
48. Starke A, Wuthrich RP, and Waeckerle-Men Y. TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol 2007; 107(1):e22-29; PMID:17671397; https://doi.org/10.1159/000106506
49. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22(10):1686-1698; PMID:21411626; https://doi.org/10.1091/mbc.E11-02-0103
50. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10(24):4256-4271; PMID:22134354; https://doi.org/10.4161/cc.10.24.18552
51. Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, Dai Y, Zhou X. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011; 440(1):23-31; PMID:21770894; https://doi.org/10.1042/BJ20111006
52. Miguez DG, Gil-Guinon E, Pons S, Marti E. Smad2 and Smad3 cooperate and antagonize simultaneously in vertebrate neurogenesis. J Cell Sci 2013; 126(Pt 23):5335-5343; PMID:24105267; https://doi.org/10.1242/jcs.130435
53. Liu L, Liu X, Ren X, Tian Y, Chen Z, Xu X, Du Y, Jiang C, Fang Y, Liu Z, et al. Smad2 and Smad3 have differential sensitivity in relaying TGFbeta signaling and inversely regulate early lineage specification. Sci Rep 2016; 6:21602; PMID:26905010; https://doi.org/10.1038/srep21602
54. Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, et al. TGFbeta1-mediated SMAD3 enhances PD-1 expression on Antigen-Specific T cells in cancer. Cancer Discov 2016; 6(12):1366-1381; PMID:27683557; https://doi.org/10.1158/2159-8290.CD-15-1347
55. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3(12):1355-1363; PMID:24078774; https://doi.org/10.1158/2159-8290.CD-13-0310
56. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29(34):4741-4751; PMID:20531305; https://doi.org/10.1038/onc.2010.215
57. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther 2013; 12(9):1805-1815; PMID:23783250; https://doi.org/10.1158/1535-7163.MCT-12-1007
58. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015; 9:4479-4499; PMID:26309397; https://doi.org/10.2147/DDDT.S86621
59. Scognamiglio G, De Chiara A, Di Bonito M, Tatangelo F, Losito NS, Anniciello A, De Cecio R, D'Alterio C, Scala S, Cantile M, et al. Variability in immunohistochemical detection of programmed death ligand 1 (PD-L1) in cancer tissue types. Int J Mol Sci 2016; 17(5); pii:E790; PMID:27213372; https://doi.org/10.3390/ijms17050790